Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines.
暂无分享,去创建一个
S. Hartmann | M. Flentje | G. Krohne | V. Sukhorukov | C. Djuzenova | Sebastian Kuger | A. Katzer | N. Günther | Marlene Biehl | Heiko Zimmermann | Eike Worschech
[1] E. Beierle,et al. FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma , 2013, Clinical & Experimental Metastasis.
[2] S. Ramalingam,et al. Hsp90 inhibitors. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] M. Flentje,et al. Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 May Exert a Significant Radiosensitization on Tumor Cells along with a Cell Type-Specific Cytotoxicity. , 2012, Translational oncology.
[4] E. Wattel,et al. Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase , 2012, Oncotarget.
[5] Sven Diederichs,et al. The hallmarks of cancer , 2012, RNA biology.
[6] M. Flentje,et al. Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia , 2012, Cancer biology & therapy.
[7] M. Murata,et al. Heat shock protein 90 maintains the tumour-like character of rheumatoid synovial cells by stabilizing integrin-linked kinase, extracellular signal-regulated kinase and protein kinase B. , 2011, Rheumatology.
[8] S. Ponnambalam,et al. Hypoxia differentially regulates VEGFR1 and VEGFR2 levels and alters intracellular signaling and cell migration in endothelial cells. , 2011, Biochemical and biophysical research communications.
[9] N. Cordes,et al. The Role of the Focal Adhesion Protein PINCH1 for the Radiosensitivity of Adhesion and Suspension Cell Cultures , 2010, PloS one.
[10] M. Jensen,et al. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction , 2010, British Journal of Cancer.
[11] J. Brueggen,et al. Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800 , 2010, Molecular Cancer Therapeutics.
[12] M. Jensen,et al. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. , 2010, Current opinion in drug discovery & development.
[13] Michael C. Ostrowski,et al. Erk1 and Erk2 Regulate Endothelial Cell Proliferation and Migration during Mouse Embryonic Angiogenesis , 2009, PloS one.
[14] E. Gulbins,et al. Induction of Membrane Ceramides: A Novel Strategy to Interfere with T Lymphocyte Cytoskeletal Reorganisation in Viral Immunosuppression , 2009, PLoS pathogens.
[15] X. Barril,et al. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. , 2009, Journal of Medicinal Chemistry.
[16] J. Bai,et al. Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion , 2009, British Journal of Cancer.
[17] M. Taniwaki,et al. A novel amplification target, ARHGAP5, promotes cell spreading and migration by negatively regulating RhoA in Huh-7 hepatocellular carcinoma cells. , 2009, Cancer letters.
[18] Kazunori Kihara,et al. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. , 2009, Anticancer research.
[19] A. Robles,et al. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair , 2008, Molecular Cancer Therapeutics.
[20] L. Pearl,et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. , 2008, Cancer research.
[21] Richard P. Hill,et al. Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability , 2008, Nature Reviews Cancer.
[22] Mike Wood,et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.
[23] Jonathan M Lee,et al. Geldanamycin Anisimycins Activate Rho and Stimulate Rho- and ROCK-Dependent Actin Stress Fiber Formation , 2007, Molecular Cancer Research.
[24] Stephen L. Abrams,et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.
[25] A. Wiestner,et al. Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines , 2006, Clinical Cancer Research.
[26] Huifang M. Zhang,et al. Induced focal adhesion kinase expression suppresses apoptosis by activating NF-kappaB signaling in intestinal epithelial cells. , 2006, American journal of physiology. Cell physiology.
[27] 中村雅阳,et al. Novel hsp90 inhibitors , 2006 .
[28] T. Tsuruo,et al. Stabilization of integrin-linked kinase by binding to Hsp90. , 2005, Biochemical and biophysical research communications.
[29] Ken Jacobson,et al. MAP kinases and cell migration , 2004, Journal of Cell Science.
[30] L. Neckers,et al. Heat shock protein 90 , 2003, Current opinion in oncology.
[31] A. Hall,et al. Rho GTPases in cell biology , 2002, Nature.
[32] J. Kuratsu,et al. Inhibition of migration of human glioblastoma cells by cerivastatin in association with focal adhesion kinase (FAK). , 2002, Cancer Letters.
[33] D. Picard,et al. Heat-shock protein 90, a chaperone for folding and regulation , 2002, Cellular and Molecular Life Sciences CMLS.
[34] Guido Reifenberger,et al. Pten signaling in gliomas. , 2002, Neuro-oncology.
[35] S. Dedhar,et al. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9) , 2000, Oncogene.
[36] S. Hanks,et al. Anti-apoptotic Role of Focal Adhesion Kinase (FAK): Induction of Inhibitor-of-Apoptosis Proteins and Apoptosis Suppression by the Overexpression of FAK in a Human Leukemic Cell Line, HL-60 , 2000 .
[37] S. Hanks,et al. Anti-apoptotic Role of Focal Adhesion Kinase (FAK) , 2000, The Journal of Biological Chemistry.
[38] T G Myers,et al. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. , 1999, Journal of the National Cancer Institute.
[39] B. van de Water,et al. Dephosphorylation of Focal Adhesion Kinase (FAK) and Loss of Focal Contacts Precede Caspase-mediated Cleavage of FAK during Apoptosis in Renal Epithelial Cells* , 1999, The Journal of Biological Chemistry.
[40] D. Schlaepfer,et al. Signaling through focal adhesion kinase. , 1999, Progress in biophysics and molecular biology.
[41] K. Kaibuchi,et al. Formation of Actin Stress Fibers and Focal Adhesions Enhanced by Rho-Kinase , 1997, Science.
[42] E. Ruoslahti,et al. Control of adhesion-dependent cell survival by focal adhesion kinase , 1996, The Journal of cell biology.
[43] I. Fidler,et al. Critical factors in the biology of human cancer metastasis. , 1995, The American surgeon.
[44] G. Johnson,et al. Gα12 and Gα13 Stimulate Rho-dependent Stress Fiber Formation and Focal Adhesion Assembly (*) , 1995, The Journal of Biological Chemistry.
[45] I. Fidler,et al. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. , 1990, Cancer research.
[46] Aftab Taiyab,et al. HSP90 modulates actin dynamics: inhibition of HSP90 leads to decreased cell motility and impairs invasion. , 2011, Biochimica et biophysica acta.
[47] M. Egorin,et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts , 2004, Cancer Chemotherapy and Pharmacology.
[48] L. Neckers,et al. The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase. , 1999, Molecular genetics and metabolism.